Enlitux (Cetuximab Beta Injection) – Colorectal Cancer | HongKong DengYue Medicine

Cetuximab Beta Injection Application Scope

Cetuximab Beta Injection is indicated for the treatment of:

• Colorectal cancer (metastatic or unresectable, RAS wild-type)

• Squamous cell carcinoma of the head and neck (locally advanced or recurrent/metastatic)

It is a monoclonal antibody that targets epidermal growth factor receptor (EGFR), inhibiting tumor cell proliferation, survival, and metastasis. Cetuximab Beta can be used as monotherapy or in combination with chemotherapy, depending on the clinical context.

Cetuximab Beta Injection Characteristics

• Ingredients: Cetuximab beta

• Properties:​ Recombinant human-murine chimeric monoclonal antibody targeting EGFR

• Packaging Specification:​ 100 mg/20 mL per vial × 1 vial/box

• Storage:​ Store at 2–8°C; do not freeze; protect from light

• Expiry Date: As indicated on packaging (typically 24 months from manufacturing date)

• Executive Standard: ​In accordance with the pharmacopoeia and regulatory requirements

• Approval Number: As per national drug regulatory authority

• Date of Revision: Latest update per product labeling

• Manufacturer: As per product packaging

Guidelines for the Use of Enlitux

• Dosage and Administration:

  • Recommended Dose:

    • Initial loading dose: 400 mg/m², followed by 250 mg/m² weekly (for colorectal cancer)

    • Dose adjustments may be required based on toxicity and clinical response

  • Administration: Intravenous infusion

  • Missed Dose:​ Administer as soon as possible; continue with regular schedule

• Adverse Reactions:

  • Common Adverse Reactions: Acneiform rash, infusion reactions, diarrhea, fatigue, hypomagnesemia

  • Serious Adverse Reactions: Severe infusion reactions, cardiopulmonary arrest, interstitial lung disease, severe skin toxicity

    ​

• Contraindications:

  • Known hypersensitivity to cetuximab beta or any component of the formulation

  • History of severe infusion reactions to monoclonal antibodies

• Precautions:

  • Monitor for infusion reactions during and after administration.

  • Correct electrolyte abnormalities, especially hypomagnesemia.

  • Please exercise caution in patients with cardiac disease or severe dermatologic conditions.

Cetuximab Beta Injection Interactions

• Monitor for infusion reactions during and after administration.

• Correct electrolyte abnormalities, especially hypomagnesemia.

• Please exercise caution in patients with cardiac disease or severe dermatologic conditions.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.